证券代码：688108 证券简称：赛诺医疗 公告编号：2025-042 赛诺医疗科学技术股份有限公司关于公司 棘突球囊产品获得国外医疗器械注册证的自愿性披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 近日，赛诺医疗科学技术股份有限公司（以下简称"赛诺医疗"或"公司"） TRADENTTM冠状动脉棘突 球囊扩张导管获得泰国公共卫生部下属的国家级监管机构泰国食品药品监督管理局（Thailand Food and Drug Administration，简称 Thai FDA 或 TFDA）的批准，在泰国获得《医疗器械注册证》。现将相关情 况公告如下： 一、《医疗器械注册证》内容 注册证编号：68-2-1-2-0007694 产品名称：冠状动脉棘突球囊扩张导管(TRADENTTM海神戟TM)） 二、医疗器械基本情况 本次获得泰国医疗器械注册证的TRADENTTM冠状动脉棘突球囊扩张导管是公司自主研发并在国内棘 突球囊品类中最先获批的一款产品，主要用于PTCA中对于血管狭窄病变进行扩张治疗。 该产品在设计上兼顾了通过性、 ...

Summary of Key Points Core Viewpoint - The announcement details the shareholding status and a planned share reduction by a major shareholder of Sino Medical Science Technology Co., Ltd. due to personal funding needs [1][2]. Shareholding Status - As of the announcement date, the major shareholder, Mr. Guo Yanchao, holds 20,840,854 shares, representing 5.01% of the total shares of the company [2]. - Mr. Guo acquired 340,854 shares through secondary market trading, which accounts for 0.08% of the total shares [1]. Reduction Plan Details - Mr. Guo plans to reduce his holdings by up to 168,000 shares, which is not more than 0.04% of the total share capital, through block trading within three months from September 22, 2025, to December 21, 2025 [2]. - The shares to be reduced are sourced from shares acquired through competitive bidding in the secondary market [2]. Previous Reduction Activity - In the past 12 months, Mr. Guo has reduced his holdings by 1,930,000 shares, which is 0.46% of the total shares, at a price range of 12.80 to 12.90 yuan per share [2]. Compliance and Regulations - The reduction plan complies with relevant laws and regulations, including the Company Law and Securities Law of the People's Republic of China [3]. - The major shareholder has no other arrangements regarding the reduction and has not made any commitments regarding shareholding changes [2][3].

证券代码：688108 证券简称：赛诺医疗 公告编号：2025-042 赛诺医疗科学技术股份有限公司关于公司 棘突球囊产品获得国外医疗器械注册证的自愿性披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，赛诺医疗科学技术股份有限公司（以下简称"赛诺医疗"或"公司"） TRADENT TM 冠状动脉棘突球囊扩张导管获得泰国公共卫生部下属的国家级监管机构泰 国食品药品监督管理局（Thailand Food and Drug Administration，简称 Thai FDA 或 TFDA）的批准，在泰国获得《医疗器械注册证》。现将相关情况公告如下： 一、《医疗器械注册证》内容 注册证编号：68-2-1-2-0007694 该产品在设计上兼顾了通过性、切割效果及安全性三大核心需求，采用棘突丝"螺旋 式"布局在球囊表面，使球囊具有强大嵌入能力的同时还具有较好的通过性。球囊充压后， 能够有效锁定钙化斑块并进行 360°全方位的斑块剥离，从而实现可控且高效的预处理。 由于镍钛合金具有形状记忆的优点，该产品在球囊卸压后，棘 ...

Group 1 - The company announced that its TRADENTTM coronary balloon dilation catheter has received approval from the Thai FDA, a national regulatory body under the Ministry of Public Health in Thailand [1] - The medical device registration certificate number is 68-2-1-2-0007694, valid until December 31, 2029 [1] - This product is the first of its kind in the domestic market for balloon catheters, primarily used for the expansion treatment of vascular stenosis lesions during PTCA [1]

Core Viewpoint - Sino Medical (688108.SH) has received approval from the Thai Food and Drug Administration for its self-developed TRADENTTM coronary artery balloon dilation catheter, marking the first overseas registration certificate for this product, which will enhance the company's overseas product offerings [1] Group 1 - The TRADENTTM catheter is primarily used for the expansion treatment of vascular stenosis lesions during PTCA (Percutaneous Transluminal Coronary Angioplasty) [1] - This approval represents a significant milestone for Sino Medical as it expands its international market presence [1] - The product's registration in Thailand will effectively increase the variety of products available for sale in the company's overseas business [1]

证券之星消息，8月29日医疗器械板块较上一交易日上涨0.11%，透景生命领涨。当日上证指数报收于 3857.93，上涨0.37%。深证成指报收于12696.15，上涨0.99%。医疗器械板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 600807 | 济高发展 | 3.11 | -4.89% | 33.54万 | | 1.06亿 | | 301363 | 美好医疗 | 24.09 | -4.25% | 22.96万 | | 5.56 Z | | 6668889 | 硕世生物 | 61.71 | -3.46% | 1.59万 | | 9923.51万 | | 688217 | 睿昂基因 | 29.22 | -3.18% | 1.58万 | | 4647.36万 | | 300289 | 利德曼 | 8.23 | -3.18% | 20.74万 | | 1.72亿 | | 688050 | 爰博医疗 | 77.81 | -2.96% | 6.24万 | | 4. ...

Group 1 - The core viewpoint of the news highlights the strong performance of the medical device sector, with the medical device ETF fund (159797) seeing significant net subscriptions and capital inflow [1] - The medical device ETF fund (159797) has accumulated over 160 million yuan in net subscriptions in the past 20 days, indicating strong investor interest [1] - Major stocks within the medical device ETF fund have shown positive performance, with notable gains from companies like Tsinghua Tongfang and Jimin Health [1][2] Group 2 - According to Everbright Securities, there is an expectation for supportive policies from the drug regulatory authority to drive growth in high-end imaging equipment, surgical robots, and AI+medical sectors, benefiting leading companies in these niches [3] - The medical device industry, particularly in equipment, has seen a significant recovery in demand since the second half of 2024, with expectations for continued growth in company financials [3] - The investment strategy for 2025 emphasizes structural selection of investment opportunities based on payment willingness and ability, focusing on three main payment channels: hospital payments, out-of-pocket payments, and overseas payments [3] Group 3 - Guotai Junan Securities notes that the global brain-computer interface market is at a critical turning point, with projections for the medical application market to reach $40 billion by 2030 and $145 billion by 2040 [4] - The brain-computer interface industry is expected to accelerate due to supportive policies, with key technology breakthroughs anticipated by 2027 [4][5] - The establishment of clear pricing standards for brain-computer interface services by the National Medical Insurance Bureau is expected to enhance hospital procurement confidence and facilitate the application of this technology in healthcare [5] Group 4 - The medical device ETF fund (159797) covers a wide range of sectors including medical equipment, in vitro diagnostics, and high-value consumables, with the top ten weighted stocks accounting for nearly 44% of the fund [6] - The top weighted stocks in the medical device ETF include Mindray Medical, United Imaging, and Aimeike, indicating a diverse portfolio within the medical device sector [6]

Company Overview - Sino Medical Science Technology Co., Ltd. is located in Tianjin and was established on September 21, 2007, with its listing date on October 30, 2019 [1] - The company specializes in the research, production, and sales of high-end interventional medical devices, focusing on cardiovascular, cerebrovascular, and structural heart disease treatment areas [1] - The revenue composition of the main business includes stents (59.76%), balloons (32.68%), and others (7.56%) [1] Financial Performance - As of June 30, the number of shareholders increased to 11,100, a rise of 0.42%, with an average of 37,515 circulating shares per person, up by 0.21% [2] - For the first half of 2025, the company achieved a revenue of 240 million yuan, representing a year-on-year growth of 12.53%, while the net profit attributable to shareholders was 13.84 million yuan, up by 296.54% [2] Stock Performance - On August 29, the stock price of Sino Medical fell by 2.10% to 31.20 yuan per share, with a trading volume of 294 million yuan and a turnover rate of 2.20%, resulting in a total market capitalization of 12.981 billion yuan [1] - Year-to-date, the stock price has increased by 219.67%, with a recent decline of 4.59% over the last five trading days, but a rise of 112.97% over the last 20 days and 174.41% over the last 60 days [1] - The company has appeared on the daily trading leaderboard six times this year, with the most recent occurrence on August 22 [1] Dividend Information - Since its A-share listing, Sino Medical has distributed a total of 41 million yuan in dividends, with no dividends paid in the last three years [3]

Group 1 - On August 29, seven companies listed on the Sci-Tech Innovation Board announced share reduction plans, with an estimated total reduction of approximately 2.647 billion yuan based on the closing price on August 28 [1] - The reduction plans involve various stakeholders, including controlling shareholders, employee stock ownership plans, and shareholders holding more than 5% of the shares, utilizing methods such as centralized bidding, block trading, and inquiry transfer [1] - Aojie Technology announced that its shareholder, Alibaba Network, plans to reduce its holdings by up to 12.549 million shares, accounting for no more than 3% of the company's total share capital, through block trading and centralized bidding within three months after the announcement [1] Group 2 - As of the announcement date, Alibaba Network directly holds 64.5574 million shares of Aojie Technology, representing 15.4333% of the company's total share capital, with these shares originating from the company's initial public offering prior to the listing [1]

Group 1 - The core point of the announcement is that Guo Yanchao, a major shareholder of Sino Medical, holds approximately 20.84 million shares, accounting for 5.01% of the total shares of the company [1] - Of the shares held, 20.5 million shares were acquired through a private transfer agreement in January 2024, representing 4.93% of the total shares, while about 340,000 shares were purchased through the secondary market, accounting for 0.08% [1] - Guo Yanchao plans to reduce his holdings by no more than approximately 170,000 shares, which is up to 0.04% of the total share capital, within three months after the announcement of the reduction plan [1] Group 2 - As of the announcement date, Sino Medical's revenue composition for the year 2024 is 99.83% from the medical device industry and 0.17% from other businesses [1] - The market capitalization of Sino Medical is reported to be 13.3 billion yuan [2]